<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045875</url>
  </required_header>
  <id_info>
    <org_study_id>RC-5816</org_study_id>
    <nct_id>NCT02045875</nct_id>
  </id_info>
  <brief_title>Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence</brief_title>
  <official_title>Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asthma Management Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>West Penn Allegheny Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asthma Management Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      40 subjects with moderate-to-severe asthma will be randomly selected for study in which 20,
      will be monitored for medication use (Dulera 100/5, Dulera 200/5 and Proventil HFA) over 3
      months. These intervention subjects will receive medication use feedback at each visit, while
      the control group will receive the standard of asthma care. Those interventional subjects
      with Dulera adherence&lt;60% will receive feedback based on an asthma adherence disease
      management model protocol, Asthma Adherence Pathway. Intervention clinicians will been
      trained in Motivational Interviewing to reduce subject ambivalence about medication use. The
      primary hypothesis is that subjects who receive medication monitoring and Motivational
      Interviewing adherence strategies will have better asthma control, as measured by the Asthma
      Control Questionnaire, than the control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Clinical Hypothesis: Poorly controlled subjects with moderate-to-severe asthma
      (measured by Asthma Control Questionnaire (ACQ) ≥ 1) despite treatment with Dulera, who are
      treated with the asthma adherence disease management protocol, Asthma Adherence Pathway™,
      will achieve greater asthma control than similar control subjects who are treated with the
      current standard of care.

      Primary end point: There will be four measures of Asthma Control Questionnaire (ACQ) over
      time over 3 months. The primary endpoint is the third month measure of ACQ.

      Secondary Clinical Hypothesis: The asthma adherence disease management program, Asthma
      Adherence Pathway™, will increase observed adherence to Dulera relative to a benchmark of 60%
      adherence (i.e., expected prescribed actuations).

      Secondary end points: a) Average adherence to Dulera over the three month study period

      Tertiary Clinical Hypothesis: Responses to Adult Asthma Adherence Questionnaire (AAAQ) will
      be related to Dulera Adherence

      Tertiary Study Endpoints: There will be 2 measures of the AAAQ (first and last visit) and the
      tertiary endpoint is the last visit
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2014</start_date>
  <completion_date type="Actual">July 12, 2017</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control</measure>
    <time_frame>Baseline, one, two and three months</time_frame>
    <description>Asthma Control Questionnaire measured at each office visit. ACQ integrates values by 6 clinical questions related to symptoms and the value related to FEV1% predicted with a total score ranging from 0-6 and higher values indicating poorer asthma control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to Dulera 100/5 and 200/5</measure>
    <time_frame>week 2. months 1, 2, and 3</time_frame>
    <description>Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Adherence was calculated by taking the number of doses actually taken divided by the number of doses prescribed and multiplying by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Adherence to Dulera 100/5 and 200/5</measure>
    <time_frame>3 months</time_frame>
    <description>Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Overall interval value was the mean of daily percent</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dulera adherence monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulera Standard of Asthma Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dulera standard of asthma care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulera</intervention_name>
    <description>Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
    <arm_group_label>Dulera Standard of Asthma Care</arm_group_label>
    <arm_group_label>Dulera adherence monitoring</arm_group_label>
    <other_name>mometasone furoate/formoterol fumarate dihydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Physician diagnosis of asthma of moderate severity

          2. Subjects ≥ 18 years of age

          3. Currently receiving an inhaled corticosteroid medication and being prescribed Dulera
             100/5 as part of standard of care based upon asthma severity and dosing guidelines

          4. Asthma Control Questionnaire (ACQ) result &gt; 1.0 at entry

          5. Demonstration of correct inhalation technique for use of meter-dosed inhalers (MDIs)

          6. History of reversible airway obstruction documented by treating physician Exclusion
             Criteria: intermittent asthma; emphysema, chronic obstructive pulmonary disease;
             chronic bronchitis; cystic fibrosis; medication that may have a drug interaction with
             Dulera

        Exclusion Criteria

          1. Intermittent asthma (asthma exacerbations or symptoms &lt; 3 days/week)

          2. Diagnosis of emphysema in prior year

          3. Diagnosis at any time of: chronic obstructive pulmonary disease (COPD), chronic
             bronchitis, cystic fibrosis, bronchiectasis, Churg Strauss, Wegener's, sarcoidosis,
             pulmonary hypertension or lung cancer

          4. On any medication documented to have a drug interaction with Dulera
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Gentile, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Penn Allegheny Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Penn Allegheny Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <results_first_submitted>May 11, 2018</results_first_submitted>
  <results_first_submitted_qc>June 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2018</results_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adherence monitoring</keyword>
  <keyword>Motivational Interviewing Adherence strategies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02045875/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dulera Adherence Monitoring</title>
          <description>Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
        </group>
        <group group_id="P2">
          <title>Dulera Standard of Asthma Care</title>
          <description>Dulera standard of asthma care
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dulera Adherence Monitoring</title>
          <description>Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
        </group>
        <group group_id="B2">
          <title>Dulera Standard of Asthma Care</title>
          <description>Dulera standard of asthma care
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="23" upper_limit="67"/>
                    <measurement group_id="B2" value="39" lower_limit="26" upper_limit="69"/>
                    <measurement group_id="B3" value="40" lower_limit="23" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Asthma Control</title>
        <description>Asthma Control Questionnaire measured at each office visit. ACQ integrates values by 6 clinical questions related to symptoms and the value related to FEV1% predicted with a total score ranging from 0-6 and higher values indicating poorer asthma control.</description>
        <time_frame>Baseline, one, two and three months</time_frame>
        <population>All patients who completed ACQ at 4 clinical visits were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Dulera Adherence Monitoring</title>
            <description>Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
          </group>
          <group group_id="O2">
            <title>Dulera Standard of Asthma Care</title>
            <description>Dulera standard of asthma care
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control</title>
          <description>Asthma Control Questionnaire measured at each office visit. ACQ integrates values by 6 clinical questions related to symptoms and the value related to FEV1% predicted with a total score ranging from 0-6 and higher values indicating poorer asthma control.</description>
          <population>All patients who completed ACQ at 4 clinical visits were included in the analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.857" spread="0.924"/>
                    <measurement group_id="O2" value="1.592" spread="0.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>one month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.792" spread="1.359"/>
                    <measurement group_id="O2" value="1.578" spread="0.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>two month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.345" spread="1.184"/>
                    <measurement group_id="O2" value="1.488" spread="0.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>three month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.105" spread="0.806"/>
                    <measurement group_id="O2" value="1.407" spread="0.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>Effect of interaction of time and treatment group</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Dulera 100/5 and 200/5</title>
        <description>Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Adherence was calculated by taking the number of doses actually taken divided by the number of doses prescribed and multiplying by 100.</description>
        <time_frame>week 2. months 1, 2, and 3</time_frame>
        <population>Data was only collected in the interventional group.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulera Adherence Monitoring</title>
            <description>Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Dulera 100/5 and 200/5</title>
          <description>Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Adherence was calculated by taking the number of doses actually taken divided by the number of doses prescribed and multiplying by 100.</description>
          <population>Data was only collected in the interventional group.</population>
          <units>percent of prescribed doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.75" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" spread="14.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.55" spread="19.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8" spread="19.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>correlation coefficient</param_type>
            <param_value>-0.508</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>correlation of asthma control and adherence</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Adherence to Dulera 100/5 and 200/5</title>
        <description>Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Overall interval value was the mean of daily percent</description>
        <time_frame>3 months</time_frame>
        <population>Data was only collected in the interventional group.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulera Adherence Monitoring</title>
            <description>Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Adherence to Dulera 100/5 and 200/5</title>
          <description>Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Overall interval value was the mean of daily percent</description>
          <population>Data was only collected in the interventional group.</population>
          <units>percent of prescribed doses per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.95" spread="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dulera Adherence Monitoring</title>
          <description>Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
        </group>
        <group group_id="E2">
          <title>Dulera Standard of Asthma Care</title>
          <description>Dulera standard of asthma care
Dulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew G Weinstein MD</name_or_title>
      <organization>Asthma Management Systems</organization>
      <phone>302 893 5455</phone>
      <email>agwmd@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

